View Financial HealthiTonic Holdings 배당 및 자사주 매입배당 기준 점검 0/6iTonic Holdings 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-0.5%자사주 매입 수익률총 주주 수익률-0.5%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • Jul 15Itonic Holdings Ltd. Provides Update on Development of Ai-Powered Cloud Healthcare Platform for Nuclear Medicine Treatment PlanningiTonic Holdings Ltd. has announced continued progress in the development of its next-generation AI-enabled Treatment Planning System ("TPS") Cloud Platform through Mili (Jiangsu) Medical Technology Co. Ltd. The TPS Cloud Platform is being developed to transform traditional standalone treatment planning software into a cloud-based healthcare collaboration platform by integrating artificial intelligence ("AI"), medical data connectivity, automated quality control and workflow management capabilities. Mili Medical is upgrading its traditional standalone TPS software into a browser-based cloud platform, and is expected to enable healthcare professionals to access treatment planning capabilities across multiple locations and devices without relying on local software installation, if successfully completed and registered as required by applicable laws and regulations. The platform is being developed to incorporate AI algorithms designed to assist physicians with treatment planning workflows, including target area identification, organ segmentation and optimization recommendations, with the objective of improving efficiency and reducing operational complexity. These intended capabilities remain subject to further development, testing, clinical workflow validation and applicable regulatory review. The platform is being developed with automated quality management functions designed to support treatment verification, workflow monitoring, reporting and data traceability throughout the treatment process. The modular cloud architecture is designed to support future expansion into additional healthcare applications, including medical data management, supply chain coordination, research collaboration and intelligent healthcare services. As of the date of this announcement, the Company has completed significant development milestones, including: Core cloud architecture development; Browser-based TPS functionality development; Medical data sharing framework development; Initial AI model training; Quality control rule framework development. The Company is currently conducting internal testing, system optimization and clinical workflow validation. The platform has not been clinically validated for commercial use and has not received registration, clearance or approval from applicable regulators. The Company continues to evaluate collaboration opportunities with healthcare institutions to support future commercialization and market deployment. The TPS Cloud Platform is being developed by the Company to address these limitations by creating a centralized digital environment that connects physicians, medical departments and healthcare institutions through secure cloud-based workflows. The platform is expected to provide: Browser-based treatment planning access; Multi-location collaboration capabilities; Standardized medical data management; Automated workflow monitoring; Enhanced treatment planning efficiency. A core component of the platform is the integration of artificial intelligence technology designed to support clinical decision-making. The AI module is being developed to assist with: Automated identification and segmentation of treatment areas; Intelligent treatment plan recommendations; Continuous algorithm improvement through clinical data feedback; Reduction of repetitive manual processes. The Company is also developing a comprehensive quality control module intended to create a digital monitoring framework covering key treatment planning processes. Potential capabilities include: Treatment plan verification; Automated quality checks; Data recording and traceability; Exception alerts and reporting; Integration with existing hospital information systems. Following completion and validation of the core cloud platform, the Company plans to explore additional modular applications, including: Healthcare supply chain management: Digital tracking and management of medical supplies and equipment; Nuclear medicine management: Supporting lifecycle tracking of nuclear medicine materials and related records; Medical robotics integration: Potential connection between treatment planning systems and advanced medical equipment; Clinical research and patient management tools: Supporting research collaboration and long-term patient data management. The TPS Cloud Platform is expected to be regulated as medical device software in China and remains subject to applicable regulatory requirements, including registration testing, registration application and review procedures. The platform has not received regulatory approval or registration for commercialization, and there can be no assurance as to the timing or outcome of any required registration or approval process. Any delay in completing applicable regulatory procedures could delay the platform’s commercialization and market deployment.공고 • Jun 24Itonic Holdings Ltd Announces Board and Committee Changes, Effective June 18, 2026iTonic Holdings Ltd. announced that on June 18, 2026, Mr. Bin Wu tendered his resignation as an independent director of the Company, effective June 18, 2026. Mr. Wu's resignation was due to personal reasons, and not as a result of any disagreement between Mr. Wu and the Company on any matter relating to the Company's operations, policies or practices. Concurrently with the resignation of Mr. Wu, the board of directors of the Company appointed Kun Yang to succeed Mr. Wu as a new independent director of the Company on June 18, 2026. Kun Yang was also appointed to succeed Mr. Wu as a member of the Audit Committee, the Corporate Governance and Nominating Committee and the Compensation Committee of the Company and will replace Mr. Wu as the chair of the Corporate Governance and Nominating Committee. Kun Yang will become the new chair of the Corporate Governance and Nominating Committee. Kun Yang graduated from Hunan University of Technology and Business in July 2013 and obtained a bachelor's degree in accounting. In July 2021, Kun Yang obtained a master's degree in professional accounting from Jinan University.New Risk • Jun 07New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 7x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 103% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m (US$523k revenue). Minor Risk Market cap is less than US$100m (US$32.8m market cap).Reported Earnings • Apr 01Full year 2025 earnings released: US$0.32 loss per share (vs US$0.052 loss in FY 2024)Full year 2025 results: US$0.32 loss per share (further deteriorated from US$0.052 loss in FY 2024). Net loss: US$5.10m (loss widened US$4.44m from FY 2024).공고 • Mar 25iTonic Holdings Ltd. announced that it expects to receive $20 million in fundingiTonic Holdings Ltd. announced that it has entered into a private placement subscription agreement with certain investors for a private placement offering of 100,000,000 Class A ordinary shares of par value $0.0001 per share at an issue price of $0.20 per Class A Ordinary Share for gross proceeds of $20,000,000 on March 23, 2026. The Private Placement is expected to close in April 2026, subject to satisfaction or waiver of the condition's precedent set forth in the Subscription Agreement. The Class A Ordinary Shares issued in the Private Placement are subject to a six-month lock-up period from the date of issuance.Board Change • Feb 01High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Director Pengfei Zhang is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.공고 • Jan 27iTonic Holdings Ltd. Announces Directorate and Committee Changes Effective January 22, 2026iTonic Holdings Ltd. announced that on January 22, 2026, Mr. Yun Fai Wong tendered his resignation as an independent director of the Company, effective immediately, due to personal reasons. Concurrently with the resignation of Mr. Wong, the board of directors of the Company appointed Mr. Bin Wu to succeed Mr. Wong as a new independent director of the Company on January 22, 2026. Mr. Wu was also appointed to succeed Mr. Wong as a member of the Audit Committee, the Corporate Governance and Nominating Committee and the Compensation Committee of the Company and will replace Mr. Yun Fai Wong as the chair of the Corporate Governance and Nominating Committee. Mr. Bin Wu will become the new chair of the Corporate Governance and Nominating Committee. Mr. Wu graduated from Wuhan University in July 1987 and obtained a Master of Business Administration from Duke University. The Company believes that Mr. Bin Wu qualifies as an independent director of the Company in accordance with Nasdaq Listing Rules and regulations of the Securities and Exchange Commission.New Risk • Jan 15New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 31% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.4m free cash flow). Share price has been highly volatile over the past 3 months (31% average weekly change). Earnings have declined by 113% per year over the past 5 years. Revenue is less than US$1m (US$305k revenue). Market cap is less than US$10m (US$7.50m market cap). Minor Risk Shareholders have been diluted in the past year (20% increase in shares outstanding).Reported Earnings • Dec 18First half 2025 earnings released: US$0.14 loss per share (vs US$0.024 loss in 1H 2024)First half 2025 results: US$0.14 loss per share (further deteriorated from US$0.024 loss in 1H 2024). Net loss: US$2.04m (loss widened US$1.75m from 1H 2024).New Risk • Dec 11New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.40m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 29% over the past year. Revenue is less than US$1m (US$448k revenue). Market cap is less than US$10m (US$9.40m market cap). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Shareholders have been diluted in the past year (20% increase in shares outstanding).Board Change • Dec 01High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Director Pengfei Zhang is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.공고 • Nov 27Pheton Holdings Ltd, Annual General Meeting, Dec 19, 2025Pheton Holdings Ltd, Annual General Meeting, Dec 19, 2025, at 10:00 China Standard Time. Location: the executive centre - china resources tower no., 2666 south keyuan road, nanshan district, shenzhen, ChinaNew Risk • Oct 06New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (33% average weekly change). Revenue has declined by 29% over the past year. Shareholders have been substantially diluted in the past year (73% increase in shares outstanding). Revenue is less than US$1m (US$448k revenue). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Market cap is less than US$100m (US$19.5m market cap).New Risk • Sep 10New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 73% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (33% average weekly change). Revenue has declined by 29% over the past year. Shareholders have been substantially diluted in the past year (73% increase in shares outstanding). Revenue is less than US$1m (US$448k revenue). Minor Risk Market cap is less than US$100m (US$22.2m market cap).New Risk • Jul 30New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$23.5m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (36% average weekly change). Revenue has declined by 29% over the past year. Revenue is less than US$1m (US$448k revenue). Minor Risk Market cap is less than US$100m (US$23.5m market cap).Reported Earnings • Mar 21Full year 2024 earnings released: US$0.052 loss per share (vs US$0.02 loss in FY 2023)Full year 2024 results: US$0.052 loss per share (further deteriorated from US$0.02 loss in FY 2023). Net loss: US$660.6k (loss widened 174% from FY 2023).New Risk • Feb 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (US$572k revenue). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (US$37.9m market cap).Reported Earnings • Oct 18First half 2024 earnings released: US$0.024 loss per share (vs US$0.007 loss in 1H 2023)First half 2024 results: US$0.024 loss per share (further deteriorated from US$0.007 loss in 1H 2023). Revenue: US$210.5k (down 21% from 1H 2023). Net loss: US$285.1k (loss widened 241% from 1H 2023).공고 • Sep 06Pheton Holdings Ltd has completed an IPO in the amount of $9 million.Pheton Holdings Ltd has completed an IPO in the amount of $9 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Securities Offered: 2,250,000 Price\Range: $4 Discount Per Security: $0.28Board Change • Sep 03High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Director Pengfei Zhang is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 ITOC 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: ITOC 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장iTonic Holdings 배당 수익률 vs 시장ITOC의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (ITOC)n/a시장 하위 25% (US)1.3%시장 상위 25% (US)4.1%업계 평균 (Healthcare Services)1.1%분석가 예측 (ITOC) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 ITOC 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 ITOC 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 ITOC 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: ITOC 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/17 08:48종가2026/07/17 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스iTonic Holdings Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공고 • Jul 15Itonic Holdings Ltd. Provides Update on Development of Ai-Powered Cloud Healthcare Platform for Nuclear Medicine Treatment PlanningiTonic Holdings Ltd. has announced continued progress in the development of its next-generation AI-enabled Treatment Planning System ("TPS") Cloud Platform through Mili (Jiangsu) Medical Technology Co. Ltd. The TPS Cloud Platform is being developed to transform traditional standalone treatment planning software into a cloud-based healthcare collaboration platform by integrating artificial intelligence ("AI"), medical data connectivity, automated quality control and workflow management capabilities. Mili Medical is upgrading its traditional standalone TPS software into a browser-based cloud platform, and is expected to enable healthcare professionals to access treatment planning capabilities across multiple locations and devices without relying on local software installation, if successfully completed and registered as required by applicable laws and regulations. The platform is being developed to incorporate AI algorithms designed to assist physicians with treatment planning workflows, including target area identification, organ segmentation and optimization recommendations, with the objective of improving efficiency and reducing operational complexity. These intended capabilities remain subject to further development, testing, clinical workflow validation and applicable regulatory review. The platform is being developed with automated quality management functions designed to support treatment verification, workflow monitoring, reporting and data traceability throughout the treatment process. The modular cloud architecture is designed to support future expansion into additional healthcare applications, including medical data management, supply chain coordination, research collaboration and intelligent healthcare services. As of the date of this announcement, the Company has completed significant development milestones, including: Core cloud architecture development; Browser-based TPS functionality development; Medical data sharing framework development; Initial AI model training; Quality control rule framework development. The Company is currently conducting internal testing, system optimization and clinical workflow validation. The platform has not been clinically validated for commercial use and has not received registration, clearance or approval from applicable regulators. The Company continues to evaluate collaboration opportunities with healthcare institutions to support future commercialization and market deployment. The TPS Cloud Platform is being developed by the Company to address these limitations by creating a centralized digital environment that connects physicians, medical departments and healthcare institutions through secure cloud-based workflows. The platform is expected to provide: Browser-based treatment planning access; Multi-location collaboration capabilities; Standardized medical data management; Automated workflow monitoring; Enhanced treatment planning efficiency. A core component of the platform is the integration of artificial intelligence technology designed to support clinical decision-making. The AI module is being developed to assist with: Automated identification and segmentation of treatment areas; Intelligent treatment plan recommendations; Continuous algorithm improvement through clinical data feedback; Reduction of repetitive manual processes. The Company is also developing a comprehensive quality control module intended to create a digital monitoring framework covering key treatment planning processes. Potential capabilities include: Treatment plan verification; Automated quality checks; Data recording and traceability; Exception alerts and reporting; Integration with existing hospital information systems. Following completion and validation of the core cloud platform, the Company plans to explore additional modular applications, including: Healthcare supply chain management: Digital tracking and management of medical supplies and equipment; Nuclear medicine management: Supporting lifecycle tracking of nuclear medicine materials and related records; Medical robotics integration: Potential connection between treatment planning systems and advanced medical equipment; Clinical research and patient management tools: Supporting research collaboration and long-term patient data management. The TPS Cloud Platform is expected to be regulated as medical device software in China and remains subject to applicable regulatory requirements, including registration testing, registration application and review procedures. The platform has not received regulatory approval or registration for commercialization, and there can be no assurance as to the timing or outcome of any required registration or approval process. Any delay in completing applicable regulatory procedures could delay the platform’s commercialization and market deployment.
공고 • Jun 24Itonic Holdings Ltd Announces Board and Committee Changes, Effective June 18, 2026iTonic Holdings Ltd. announced that on June 18, 2026, Mr. Bin Wu tendered his resignation as an independent director of the Company, effective June 18, 2026. Mr. Wu's resignation was due to personal reasons, and not as a result of any disagreement between Mr. Wu and the Company on any matter relating to the Company's operations, policies or practices. Concurrently with the resignation of Mr. Wu, the board of directors of the Company appointed Kun Yang to succeed Mr. Wu as a new independent director of the Company on June 18, 2026. Kun Yang was also appointed to succeed Mr. Wu as a member of the Audit Committee, the Corporate Governance and Nominating Committee and the Compensation Committee of the Company and will replace Mr. Wu as the chair of the Corporate Governance and Nominating Committee. Kun Yang will become the new chair of the Corporate Governance and Nominating Committee. Kun Yang graduated from Hunan University of Technology and Business in July 2013 and obtained a bachelor's degree in accounting. In July 2021, Kun Yang obtained a master's degree in professional accounting from Jinan University.
New Risk • Jun 07New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 7x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 103% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 7x increase in shares outstanding). Revenue is less than US$1m (US$523k revenue). Minor Risk Market cap is less than US$100m (US$32.8m market cap).
Reported Earnings • Apr 01Full year 2025 earnings released: US$0.32 loss per share (vs US$0.052 loss in FY 2024)Full year 2025 results: US$0.32 loss per share (further deteriorated from US$0.052 loss in FY 2024). Net loss: US$5.10m (loss widened US$4.44m from FY 2024).
공고 • Mar 25iTonic Holdings Ltd. announced that it expects to receive $20 million in fundingiTonic Holdings Ltd. announced that it has entered into a private placement subscription agreement with certain investors for a private placement offering of 100,000,000 Class A ordinary shares of par value $0.0001 per share at an issue price of $0.20 per Class A Ordinary Share for gross proceeds of $20,000,000 on March 23, 2026. The Private Placement is expected to close in April 2026, subject to satisfaction or waiver of the condition's precedent set forth in the Subscription Agreement. The Class A Ordinary Shares issued in the Private Placement are subject to a six-month lock-up period from the date of issuance.
Board Change • Feb 01High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Director Pengfei Zhang is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
공고 • Jan 27iTonic Holdings Ltd. Announces Directorate and Committee Changes Effective January 22, 2026iTonic Holdings Ltd. announced that on January 22, 2026, Mr. Yun Fai Wong tendered his resignation as an independent director of the Company, effective immediately, due to personal reasons. Concurrently with the resignation of Mr. Wong, the board of directors of the Company appointed Mr. Bin Wu to succeed Mr. Wong as a new independent director of the Company on January 22, 2026. Mr. Wu was also appointed to succeed Mr. Wong as a member of the Audit Committee, the Corporate Governance and Nominating Committee and the Compensation Committee of the Company and will replace Mr. Yun Fai Wong as the chair of the Corporate Governance and Nominating Committee. Mr. Bin Wu will become the new chair of the Corporate Governance and Nominating Committee. Mr. Wu graduated from Wuhan University in July 1987 and obtained a Master of Business Administration from Duke University. The Company believes that Mr. Bin Wu qualifies as an independent director of the Company in accordance with Nasdaq Listing Rules and regulations of the Securities and Exchange Commission.
New Risk • Jan 15New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 31% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$3.4m free cash flow). Share price has been highly volatile over the past 3 months (31% average weekly change). Earnings have declined by 113% per year over the past 5 years. Revenue is less than US$1m (US$305k revenue). Market cap is less than US$10m (US$7.50m market cap). Minor Risk Shareholders have been diluted in the past year (20% increase in shares outstanding).
Reported Earnings • Dec 18First half 2025 earnings released: US$0.14 loss per share (vs US$0.024 loss in 1H 2024)First half 2025 results: US$0.14 loss per share (further deteriorated from US$0.024 loss in 1H 2024). Net loss: US$2.04m (loss widened US$1.75m from 1H 2024).
New Risk • Dec 11New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.40m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 29% over the past year. Revenue is less than US$1m (US$448k revenue). Market cap is less than US$10m (US$9.40m market cap). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Shareholders have been diluted in the past year (20% increase in shares outstanding).
Board Change • Dec 01High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Director Pengfei Zhang is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
공고 • Nov 27Pheton Holdings Ltd, Annual General Meeting, Dec 19, 2025Pheton Holdings Ltd, Annual General Meeting, Dec 19, 2025, at 10:00 China Standard Time. Location: the executive centre - china resources tower no., 2666 south keyuan road, nanshan district, shenzhen, China
New Risk • Oct 06New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (33% average weekly change). Revenue has declined by 29% over the past year. Shareholders have been substantially diluted in the past year (73% increase in shares outstanding). Revenue is less than US$1m (US$448k revenue). Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Market cap is less than US$100m (US$19.5m market cap).
New Risk • Sep 10New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 73% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (33% average weekly change). Revenue has declined by 29% over the past year. Shareholders have been substantially diluted in the past year (73% increase in shares outstanding). Revenue is less than US$1m (US$448k revenue). Minor Risk Market cap is less than US$100m (US$22.2m market cap).
New Risk • Jul 30New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$23.5m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (36% average weekly change). Revenue has declined by 29% over the past year. Revenue is less than US$1m (US$448k revenue). Minor Risk Market cap is less than US$100m (US$23.5m market cap).
Reported Earnings • Mar 21Full year 2024 earnings released: US$0.052 loss per share (vs US$0.02 loss in FY 2023)Full year 2024 results: US$0.052 loss per share (further deteriorated from US$0.02 loss in FY 2023). Net loss: US$660.6k (loss widened 174% from FY 2023).
New Risk • Feb 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (US$572k revenue). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (US$37.9m market cap).
Reported Earnings • Oct 18First half 2024 earnings released: US$0.024 loss per share (vs US$0.007 loss in 1H 2023)First half 2024 results: US$0.024 loss per share (further deteriorated from US$0.007 loss in 1H 2023). Revenue: US$210.5k (down 21% from 1H 2023). Net loss: US$285.1k (loss widened 241% from 1H 2023).
공고 • Sep 06Pheton Holdings Ltd has completed an IPO in the amount of $9 million.Pheton Holdings Ltd has completed an IPO in the amount of $9 million. Security Name: Class A Ordinary Shares Security Type: Common Stock Securities Offered: 2,250,000 Price\Range: $4 Discount Per Security: $0.28
Board Change • Sep 03High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Director Pengfei Zhang is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.